Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estradiol/nomegestrol monophasic - Merck & co.

Next Previous
Drug Profile

Estradiol/nomegestrol monophasic - Merck & co.

Alternative Names: E2-Nomac monophasic; E2/Nomac monophasic; EMM-310066; IOA; MK-8175A; NOMAC-E2; Nomac-E2 monophasic; NOMAC/E2; Nomac/E2 monophasic; Nomegestrol acetate/17 beta-estradiol; Nomegestrol acetate/estradiol; Nomegestrol/estradiol; Org 10486-0/Org 2317; SCH 900121; Zoely

Latest Information Update: 29 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theramex SAM
  • Developer Merck & Co
  • Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Pregnadienes; Progesterone congeners; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 29 Oct 2021 Launched for Pregnancy (Prevention) in Ukraine, Colombia, Turkey, Austria, Germany, Italy, Russia (PO)
  • 17 Sep 2020 Theramex and Consilient Health collaborate to distribute Estradiol/nomegestrol (Zoely®) in Ireland and Nordic countries
  • 24 Jan 2020 Theramex to acquire further commercial rights to estradiol/nomegestrol monophasic for Pregnancy (Prevention)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top